^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Renal Cell Carcinoma
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor) +
    Pegasys (pegylated interferon α -2a) (IFNα stimulant)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    02/26/2004
    Excerpt:
    Avastin is a vascular endothelial growth factor inhibitor indicated for the treatment of:...Metastatic renal cell carcinoma in combination with interferon alfa.
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    European Medicines Agency
    Excerpt:
    Bevacizumab in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer.